Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients
Journal of Pharmaceutical and Biomedical Analysis · 2023
DOI: 10.1016/j.jpba.2023.115279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2023. Verfasst von Ping Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Venetoclax, an orally bioavailable BCL-2 inhibitor, has been regarded as a breakthrough for the treatment of leukemia but has a wide interindividual variability and drug-drug interaction in pharmacokinetics. In this study, a simple and sensitive ultra-high performance liquid chromatography-tandem with mass spectrometry method was established and fully validated to quantify venetoclax and voriconazole simultaneously in human plasma. After protein precipitation, the analytes were separated on a Hypersil GOLD C18 column (3 µm, 2.1 × 50 mm) by gradient elution. The mass detection was operated under multiple reaction monitoring mode at m/z 868.5 →636.2 for venetoclax, 350.0 → 127.0 for voriconazole and 353.0 → 127.0 for voriconazole-D3(Internal Standard). The calibration ranges were 0.1-10 μg/mL for venetoclax and 0.05-10 μg/mL for voriconazole with correlation coefficients (r2)>0.998. The validated method was successfully applied to the pharmacokinetic study in acute myeloid leukemia patients receiving venetoclax with or without voriconazole. The results suggested that co-treatment with 200 mg q12h voriconazole, the peak concentration of venetoclax (100 mg qd) could be raised to the same level as the 400 mg qd group. However, the trough concentration of venetoclax (100 mg qd) was much higher than that of the 400 mg qd group. Therapeutic drug monitoring might give some guidance for the adjustment of dosing regimens to guarantee the drug efficacy and safety of patients to some extent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China.
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China.
- Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China. Electronic address: guonan8910@163.com.
Zitieren
APA
Gao, P., Zhang, W., Fang, X., Leng, B., Zhang, Y., Liu, X., Wang, X., & Guo, N. (2023). Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2023.115279
Vancouver
Gao P, Zhang W, Fang X, Leng B, Zhang Y, Liu X, et al. Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients. Journal of Pharmaceutical and Biomedical Analysis. 2023. doi:10.1016/j.jpba.2023.115279
BibTeX
@article{Gao2023,
author = {Gao, Ping and Zhang, Wen and Fang, Xiaosheng and Leng, Bing and Zhang, Yahui and Liu, Xin and Wang, Xin and Guo, Nan},
title = {Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2023},
doi = {10.1016/j.jpba.2023.115279}
}
EUVIMED